BMRN - Biomarin Pharmaceutical - Stock Forecast

Healthcare - Sector
Coverage Profile Stock analysts Price Targets & Ratings Chart Insider Trading

BMRN is currently covered by 25 analysts with an average price target of $88.52. This is a potential upside of $30.08 (51.47%) from yesterday's end of day stock price of $58.44.

Biomarin Pharmaceutical's activity chart (see below) currently has 819 price targets and 609 ratings on display. The stock rating distribution of BMRN is 78.95% BUY and 21.05% HOLD.

Stock Analyst Price Targets - Review

Analysts average stock forecasts to be materialized ratio is 43.02% with an average time for these price targets to be met of 325.78 days.

Highest price target for BMRN is $124, Lowest price target is $55, average price target is $88.52.

Most recent stock forecast was given by MITCHELL KAPOOR from HC WAINWRIGHT on 10-Sep-2026.

Overview

BioMarin Pharmaceutical . is a biotechnology company that specializes in the development and commercialization of therapies for rare and life-threatening diseases. The company’s main focus is on the development of therapies for patients with genetic disorders.

Pipeline

BioMarin’s commercial products include Vimizim, Naglazyme, Kuvan, Palynziq, Brineura, Voxzogo, and Aldurazyme, which are used for the treatment of various rare diseases such as mucopolysaccharidosis, phenylketonuria, and ceroid lipofuscinosis.

The company is also developing gene therapies for hemophilia A, Hereditary Angioedema, and primary hyperoxaluria.

Collaborations

BioMarin has license and collaboration agreements with other pharmaceutical companies, such as Sarepta Therapeutics, Ares Trading S.A., Catalyst Pharmaceutical Partners., and Asubio Pharma.

History

BioMarin Pharmaceutical Inc. was incorporated in 1996 and is headquartered in San Rafael, California.

Currently out of the existing stock ratings of BMRN, 45 are a BUY (78.95%), 12 are a HOLD (21.05%).

Analyst name

Rating

Current price target

Potential Upside

Previous price target

Date of last PT

Price targets met ratio

Average potential upside

Average Days to Hit Target

Performance score

Hold Since 08-Sep-2025

$60

$-0.26 (-0.43%)

$60

22 days ago
(10-Sep-2026)

5/9 (55.56%)

$-5.51 (-8.41%)

32

Buy Since 06-Feb-2026

$90

$29.74 (49.35%)

$88

1 months 1 days ago
(01-Sep-2026)

0/3 (0%)

$25.16 (38.80%)

Buy Since 10-Jan-2022

$105

$44.74 (74.24%)

$110

1 months 1 days ago
(31-Aug-2026)

3/11 (27.27%)

$39.77 (60.97%)

269

Buy Since 19-Aug-2026

$98

$37.74 (62.63%)

$82

1 months 13 days ago
(19-Aug-2026)

4/11 (36.36%)

$28.67 (41.35%)

105

Buy Since 20-Jan-2016

$111

$50.74 (84.20%)

$105

1 months 15 days ago
(17-Aug-2026)

8/17 (47.06%)

$44.36 (66.57%)

565

Show more analysts

Please expand the browser size to see the chart

What is BMRN (Biomarin Pharmaceutical) average time for price targets to be met?

On average it took 326 days for the stock forecasts to be reached, with an average price target met ratio of 43.02%.

Which analyst most recently updated their price target on BMRN (Biomarin Pharmaceutical)?

Mitchell Kapoor

Which analyst has the most public recommendations on BMRN (Biomarin Pharmaceutical)?

Mitchell Kapoor has 31 price targets and 16 ratings on BMRN

Which analyst is the currently most bullish on BMRN (Biomarin Pharmaceutical)?

Ying Huang with the highest potential upside of $104.74

Which analyst is the currently most reserved on BMRN (Biomarin Pharmaceutical)?

Mitchell Kapoor with the lowest potential downside of -$4
✖

To continue looking at which analysts cover the stock please register to the basic or advanced membership

To continue looking at analysts data please register to the advanced membership

What is AnaChart?